Document is current
Any future updates will be listed below
-
Authors
Dubrot, Juan
Du, Peter P. http://orcid.org/0000-0003-2652-0541
Lane-Reticker, Sarah Kate
Kessler, Emily A.
Muscato, Audrey J. http://orcid.org/0000-0003-2009-6313
Mehta, Arnav
Freeman, Samuel S. http://orcid.org/0000-0001-8285-0057
Allen, Peter M.
Olander, Kira E. http://orcid.org/0000-0002-3356-7631
Ockerman, Kyle M.
Wolfe, Clara H.
Wiesmann, Fabius
Knudsen, Nelson H. http://orcid.org/0000-0002-0384-1097
Tsao, Hsiao-Wei
Iracheta-Vellve, Arvin http://orcid.org/0000-0002-6635-3904
Schneider, Emily M. http://orcid.org/0000-0001-5778-9119
Rivera-Rosario, Andrea N.
Kohnle, Ian C.
Pope, Hans W.
Ayer, Austin
Mishra, Gargi http://orcid.org/0000-0002-4063-6797
Zimmer, Margaret D. http://orcid.org/0000-0002-3317-6569
Kim, Sarah Y.
Mahapatra, Animesh
Ebrahimi-Nik, Hakimeh
Frederick, Dennie T. http://orcid.org/0000-0003-3355-5267
Boland, Genevieve M.
Haining, W. Nicholas http://orcid.org/0000-0001-7871-3762
Root, David E. http://orcid.org/0000-0001-5122-861X
Doench, John G. http://orcid.org/0000-0002-3707-9889
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Yates, Kathleen B. http://orcid.org/0000-0002-7383-5573
Manguso, Robert T. http://orcid.org/0000-0003-1336-413X
-
Funding
Funding for this research was provided by:
Calico Life Sciences
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 15 August 2022
First Online: 23 September 2022
Competing interests
: K.B.Y. and R.T.M. receive funding from Calico Life Sciences, LLC. P.P.D. consults for and owns equity in Related Sciences. J.G.D. consults for Agios, Foghorn Therapeutics, Maze Therapeutics, Merck and Pfizer; J.G.D. consults for and has equity in Tango Therapeutics. A.I.-V. is a current employee of AstraZeneca. W.N.H. is an employee of ArsenalBio and has equity in Merck & Co., Tango Therapeutics and ArsenalBio. H.W.P. is an employee of ArsenalBio. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS Jannsen, Merck, Vir) and is a director of Addgene, Inc. A. Mehta has consulted/advised Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, venBio Partners, BioNTech, Rheos Medicines and Checkmate Pharmaceuticals and is an equity holder in Asher Biotherapeutics and Abata Therapeutics. N.H. owns equity in BioNTech and owns equity and advises Danger Bio. R.T.M. has served as a consultant for Bristol Myers Squibb. The remaining authors declare no competing interests.
